Patents Assigned to SkyePharma Canada Inc.
-
Publication number: 20040091535Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.Type: ApplicationFiled: May 2, 2003Publication date: May 13, 2004Applicant: SKYEPHARMA CANADA INC.Inventors: Michael Vachon, Awadhesh K. Mishra, Robert A. Snow, Pol-Henri Guivarc'H
-
Publication number: 20040086571Abstract: This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal.Type: ApplicationFiled: March 17, 2003Publication date: May 6, 2004Applicant: SKYEPHARMA CANADA INC.Inventors: Pol-Henri Guivarc'h, Indu Parikh, Robert A. Snow
-
Publication number: 20030206949Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: ApplicationFiled: May 23, 2003Publication date: November 6, 2003Applicant: SkyePharma Canada Inc.Inventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Publication number: 20030194442Abstract: This invention discloses an orally administered pharmaceutical composition comprising microparticles of solid fenofibrate that are stabilized by a phospholipid surface active substance that is present during the preparation of the microparticles, wherein a therapeutically effective amount of the composition provides a quantity of fenofibrate active species to a fasted human patient in need of treatment by fenofibrate that is greater than 80% of the quantity of fenofibrate active species provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal consisting of at least 1000 calories, 50% of which are from fat.Type: ApplicationFiled: May 19, 2003Publication date: October 16, 2003Applicant: SKYEPHARMA CANADA INCInventors: Pol-Henri Guivarch, Gary W. Pace, Robert A. Snow, Awadesh K. Mishra
-
Publication number: 20030180367Abstract: The invention provides a composition comprising microparticles of a water-insoluble or poorly soluble compound, at least one phospholipid, and at least one surfactant, produced by applying an energy to a mixture comprising particles of the compound, the at least one phospholipid, and the at least one surfactant so as to obtain the microparticles. The invention also provides a process for preparing microparticles of a water-insoluble or poorly soluble compound. The process includes mixing particles of a water-insoluble or poorly soluble compound with at least one phospholipid and at least surfactant to form a mixture and applying energy to the mixture sufficient to produce microparticles of the compound. The methods of the invention allow for the production of microparticles smaller than particles produced through previously known methods and the microparticles exhibit advantageous properties including remarkable resistance to particle size growth during storage.Type: ApplicationFiled: September 30, 2002Publication date: September 25, 2003Applicant: SkyePharma Canada, Inc.Inventors: Indu Parikh, Ulagaraj Selvaraj
-
Patent number: 6604698Abstract: This invention describes a process for preparing a dispersion of solid particles of a milled substrate in a fluid carrier comprising the steps of (a) providing a plurality of large size milling media to the milling chamber of a media mill and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said milling chamber a plurality of small size milling media optionally containing additional large size milling media, a conglomerate of a solid substance comprising a substrate to be milled and optionally one or more than one surface active substance, and a fluid carrier; (c) milling said conglomerate in said milling chamber to produce very small milled substrate product particles; and (d) separating said milled substrate particles suspended in said fluid carrier from the media through said depth filter; wherein the exit screen comprises openings of size S0; the large size media have a size distribution S1 of which all are larger than S0; the small size media have a siType: GrantFiled: May 10, 2001Date of Patent: August 12, 2003Assignee: SkyePharma Canada, Inc.Inventors: Frank H. Verhoff, Robert A. Snow, Gary W. Pace
-
Patent number: 6576264Abstract: Particles of water insoluble biologically active compounds, particularly water-insoluble drugs, with an average size of 100 nm to about 300 nm, are prepared by dissolving the compound in a solution then spraying the solution into compressed gaz, liquid or supercritical fluid in the presence of appropriate surface modifiers.Type: GrantFiled: March 12, 1999Date of Patent: June 10, 2003Assignees: SkyePharma Canada Inc., Board of Regents, The University of Texas SystemInventors: Inge B Henriksen, Awadesh K. Mishra, Gary W. Pace, Keith P. Johnston, Simon Mawson
-
Patent number: 6534088Abstract: This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal.Type: GrantFiled: April 20, 2001Date of Patent: March 18, 2003Assignee: SkyePharma Canada Inc.Inventors: Pol-Henri W. Guivarc'h, Indu Parikh, Robert A. Snow